SCHEMBL20766876

SCHEMBL20766876

CNS(=O)(=O)c1ccc(NC2CCCCC2)c(-c2nnn(C3CCC3)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.38
ALOX15 P16050 1/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 1/20 0.36
YAP1 P46937 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
WNK1 Q9H4A3 2/20 0.36
CHEK1 O14757 1/20 0.36
NTRK1 P04629 1/20 0.36
MET P08581 1/20 0.36
PIM1 P11309 1/20 0.36
LTK P29376 1/20 0.36
GRK5 P34947 1/20 0.36
MAP2K2 P36507 1/20 0.36
CDK8 P49336 1/20 0.36
NEK2 P51955 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30411281 1.00 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL20766257 0.99 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL20766252 0.97 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL30410841 0.97 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL20766176 0.93 BRD4 (0.37) BRD4ALOX15YAP1KDM4EMEN1
SCHEMBL20766248 0.92 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL25789258 0.92 BRD4 (0.38) BRD4ALOX15ALDH1A1MAPTYAP1
Hydrochloric Acid SCHEMBL20766310 0.92 BRD4 (0.37) BRD4ALOX15ALDH1A1MAPTYAP1
Hydrochloric Acid SCHEMBL30411404 0.92 BRD4 (0.37) BRD4ALOX15ALDH1A1MAPTYAP1
SCHEMBL20766339 0.92 BRD4 (0.37) BRD4ALOX15ALDH1A1MAPTYAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 EP disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 CN disclosed
EP-3691623-A1 BENZOSULFONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 BRD4 7/4885ALOX15 3108/4885ALDH1A1 2161/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 BRD4 328/4885ALOX15 3548/4885ALDH1A1 3323/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 BRD4 7/4885ALOX15 3108/4885ALDH1A1 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.